1173178-36-3

Basic information

• Product Name: (S)-4,4,4-trifluoro-N-((R)-2-hydroxy-1-phenylethyl)-3-methylbutanamide
• Synonyms: (S)-4,4,4-trifluoro-N-((R)-2-hydroxy-1-phenylethyl)-3-methylbutanamide
• CAS NO: 1173178-36-3
• Molecular Weight: 275.271
• Mol File: 1173178-36-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (S)-4,4,4-trifluoro-N-((R)-2-hydroxy-1-phenylethyl)-3-methylbutanamide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4,4,4-trifluoro-N-((R)-2-hydroxy-1-phenylethyl)-3-methylbutanamide(1173178-36-3)
• EPA Substance Registry System: (S)-4,4,4-trifluoro-N-((R)-2-hydroxy-1-phenylethyl)-3-methylbutanamide(1173178-36-3)

Safety Data

• Hazardous Substances Data: 1173178-36-3(Hazardous Substances Data)

Upstream product

• 348-75-4 (-)-3-trifluoromethylbutanoic acid 
• 56613-80-0 D-2-phenylglycinol 

Downstream Products

• 1173178-12-5 (R)-4-phenyl-2-((S)-3,3,3-trifluoro-2-methylpropyl)-4,5-dihydrooxazole 

Relevant articles and documents

COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS

The invention relates to novel cycloalkyl- or cycloalkenyl-substituted pyrazolopyrimidinones of formula (I), wherein ā is selected from the group A1 consisting of a C3-C8-cycloalkyl group or a C4-C8-cycloalkenyl group, whereby the members of C3-C8-cycloalkyl group being selected from the group of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptanyl and cyclooctanyl; and the members of the C4-C8-cycloalkenyl group, being selected from cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclopentadienyl, cyclohexadienyl, cycloheptadienyl, cyclooctadienyl, cycloheptatrienyl, cyclooctathenyl, cyclooctatetraenyl. The new compounds shall be used for the manufacture of medicaments, in particular medicaments for improving perception, concentration, learning and/or memory in patients in need thereof. Chemically, the compounds are characterised as pyrazolopyrimidinones with a cycloalkyl-moiety directly bound to the 1 position of the pyrazolopyrimidinone and a second substituent in the 6 position which is bound via an optionally substituted methylene-bridge. Further aspects of the present invention refer to a process for the manufacture of the compounds and their use for producing medicaments.

1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A MODULATORS

The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones, Formula (I) with Hc is a mono-, bi- or tricyclic heterocyclyl group, the ring members of which are carbon atoms and at least 1, preferably 1, 2 or 3, heteroatom(s), which are selected from the group of nitrogen, oxygen and sulphur, which is in the form of -S(O)r - with r being 0, 1 or 2, and - said heterocyclyl group is or comprises 1 non-aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member and - said heterocyclyl group is bound to the scaffold by said 1 non- aromatic, saturated, or partly unsaturated monocyclic ring which comprises at least 1 heteroatom as ring member. According to one aspect of the invention the new compounds are for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments for the treatment of Alzheimer's disease.